SS-31 Overview
Category:
Mitochondria-targeting peptide (tetrapeptide)
How it works:
SS-31 selectively targets the inner mitochondrial membrane and binds to cardiolipin. This stabilizes cristae architecture, improves electron transport and ATP generation, and reduces pathological reactive oxygen species (ROS) and cytochrome-c peroxidase activity. The net effect is improved mitochondrial efficiency and less oxidative damage.
Alternative names:
Elamipretide, Bendavia, MTP-131, D-Arg-2′6′-dimethylTyr-Lys-Phe-NH₂.
Primary research focus:
- Primary mitochondrial myopathies
- Barth syndrome
- Heart failure / myocardial energetics
- Aging-related mitochondrial dysfunction
- Retinal (AMD)
- Other tissues with bioenergetic failure
Potential:
Clinical results have been mixed — promising preclinical data but several clinical trials have failed to meet primary endpoints in some indications; long-term human safety and efficacy data remain limited; most common adverse events reported are mild (e.g., injection-site reactions). Use remains investigational.
What Is SS-31
SS-31 is a small, cell-permeable peptide from the Szeto–Schiller family designed to concentrate at the inner mitochondrial membrane where it interacts with cardiolipin. It was developed to protect mitochondrial structure and function under stress (ischemia, genetic mitochondrial dysfunction, aging). Unlike conventional antioxidants that diffuse broadly, SS-31 acts locally at the site of mitochondrial electron transport to improve efficiency and reduce damage.
Who researchers are studying it for: people with genetically confirmed primary mitochondrial myopathy, Barth syndrome patients, heart failure with reduced ejection fraction (preclinical/early clinical), and investigators exploring retinal disease or age-related mitochondrial decline.
How SS-31 Works in the Body
- Cardiolipin binding & membrane stabilization: SS-31 binds cardiolipin in the inner mitochondrial membrane, helping preserve cristae structure and the optimal geometry for the electron transport chain (ETC). This reduces electron leak and pathological ROS generation.
- Improves electron transport and ATP synthesis: By improving the physical environment of ETC complexes, SS-31 can increase mitochondrial respiration efficiency and ATP output in stressed or failing mitochondria.
- Reduces oxidative damage & apoptosis signaling: SS-31 blunts cytochrome-c peroxidase activity and lowers oxidative damage signals that otherwise lead to mitochondrial swelling, loss of membrane potential, and cell death.
- Anti-inflammatory / cytoprotective effects: Through improved bioenergetics and lower ROS, downstream inflammatory signaling and cell stress responses are reduced — which can translate to preserved tissue function (heart, muscle, neurons, kidney, retina in models).
Key Benefits
Below are the major benefits supported by preclinical work and selected clinical signals, with an emphasis on plausible mechanisms.
1. Protects mitochondrial membranes & dynamics
By binding cardiolipin, SS-31 preserves cristae and prevents mitochondrial swelling and structural collapse observed after ischemia or in some genetic disorders. This structural protection underlies many downstream functional benefits.
2. Reduces oxidative stress and ROS-mediated damage
SS-31 lowers pathological ROS generation and cytochrome-c peroxidase activity, which can limit oxidative protein/lipid damage and reduce triggering of apoptosis in vulnerable cells (cardiomyocytes, neurons, renal cells).
3. Improves ATP production and energetic capacity
Preclinical and ex-vivo human tissue studies show improved mitochondrial respiration and ATP generation after SS-31 exposure, which can translate to better contractile or metabolic function in failing tissues.
4. Cardiac and skeletal muscle support
Animal models and human ex-vivo data suggest improved myocardial energetics; this motivated trials in heart failure and mitochondrial myopathies. Some functional endpoints (exercise capacity, mitochondrial markers) have shown improvement in open-label or extension studies.
5. Neuroprotective and retinal potential
Preclinical work links SS-31 to improved synaptic function, mitochondrial resilience in neurons, and retinal cell protection — reasons for exploration in cognitive decline models and ocular indications. Human evidence is still emerging.
6. Anti-inflammatory / cytoprotective effects across organs
Through mitochondrial stabilization and lower ROS, SS-31 reduces inflammatory signaling and tissue injury in kidney, liver, and other organs in animal models.
Clinical Studies
- MMPOWER (Primary Mitochondrial Myopathy): Early phase trials (MMPOWER-1, MMPOWER-2) tested daily subcutaneous elamipretide (commonly 40 mg/day SC for short courses such as 4 weeks). Some patients showed improvements in certain functional endpoints and mitochondrial measures, but larger, pivotal trials have had mixed results.
- Barth syndrome trial: A randomized, double-blind crossover study tested 40 mg daily SC elamipretide vs placebo in Barth syndrome patients; open-label extensions reported functional gains in longer treatment periods though initial randomized endpoints were mixed.
- Heart failure / ischemia studies: Early human infusion studies showed improved mitochondrial function ex-vivo and favorable mechanistic signals; however, clinical outcome trials have not yet delivered a broad regulatory approval for heart failure indications.
- Other indications and ongoing work: Stealth BioTherapeutics and collaborators have pursued programs in age-related macular degeneration, primary mitochondrial myopathy, and other mitochondrial-related diseases; some phase 2/3 studies have been conducted or are ongoing. Trial outcomes are heterogeneous, and as of recent reviews, results are promising mechanistically but not universally successful on primary clinical endpoints.
Bottom line on trials: Strong and consistent preclinical evidence; clinical signals exist (objective mitochondrial improvements and some functional benefits), but several randomized trials have been underwhelming on primary endpoints — prompting further investigation into dosing, patient selection, and longer treatment durations.
Safety, Side Effects, and Considerations
Safety profile (summary):
- Most clinical studies report mild adverse events, the most frequent being injection-site reactions. Serious safety signals have been uncommon in short-term studies.
- Long-term safety data are limited. Trials beyond 4–12 weeks are fewer, so chronic use safety remains incompletely characterized.
Reported side effects (from trials):
- Injection-site erythema, discomfort
- Generally mild transient systemic symptoms in a minority (e.g., headache, nausea) reported in some studies
- No consistent hematologic or cardiovascular safety signal in short trials, but large outcome trials are needed for definitive conclusions.
Considerations / Practical notes:
- SS-31/elamipretide remains investigational in most uses; access is typically via clinical trial or compassionate use programs.
- Clinical benefit may depend strongly on the underlying disease, disease stage, dose, and duration — some open-label extensions suggest longer treatment may reveal benefit not seen in short randomized windows.
- If you are reading preclinical or vendor literature, be mindful: animal models and cellular studies are not guarantees of human benefit. Always prioritize peer-reviewed clinical trial data.
Practical / Research-oriented summary
- Mechanistic rationale: Strong — targets cardiolipin, stabilizes membranes, improves ETC efficiency, lowers ROS.
- Preclinical evidence: Broad and consistent across heart, kidney, muscle, nerve, retina models.
- Human trials: Mixed — encouraging mitochondrial and some functional signals in small studies and extensions; several randomized trials have not met primary endpoints, highlighting the need for optimized trial design and patient selection.
- Safety: Generally well tolerated in short-term studies; long-term human safety still an open question.
